



MINISTRY OF INDUSTRY, BUSINESS  
AND FINANCIAL AFFAIRS

# For health and wealth

- Supporting growth in the  
Danish life science sector


May 2019



# For health and wealth

- What is Life Science?
- Why the life science sector focus?
- How did we prepare The National Growth Strategy for Life Science?
- Wich frame work conditions did we present?

# What is Life Science?






MINISTRY OF INDUSTRY, BUSINESS  
AND FINANCIAL AFFAIRS

# High growth rates in the life science industry add great value to the Danish economy




The **gross value added** in the life science industry is growing significantly




## Higher growth rates compared to the entire Danish industry

The **gross value added** in the life science industry is growing significantly




The level of **productivity** is twice as high in the life science industry compared to the rest of the private sector




1.000 DKK per employee

Life science industry's **exports** have more than doubled since 2008





**Employment  
has grown by  
18 pct. from  
2008 to 2016**



The life science industry accounted for 37 pct. of private **research and development** in Denmark in 2016

Denmark received **12 pct.** of all clinical trial applications in EU in 2017, and is ranked **first** in Europe for number of clinical trials per capita



MINISTRY OF INDUSTRY, BUSINESS  
AND FINANCIAL AFFAIRS

# The National Growth Strategy for Life Science

# How did we develop the strategy?

## Life Science Growth Team

## Recommendations


## Danish Government National Growth strategy for Life Science

- Kåre Schultz, *CEO, **Lundbeck** (Chairman)*
- Allan Flyvbjerg, *Dean, Health, **University of Aarhus***
- Anders Thelborg, *CEO, **Bristol-Myers Squibb Denmark***
- Hans Schambye, *CEO, **Galecto Biotech***
- Helle Ulrichsen, *Chairman of **Strategic Alliance for Register & Healthdata***
- Kristian Helin, *Professor, Director, Biotech Research & Innovation Centre, **University of Copenhagen***
- Lars Rasmussen, *CEO, **Coloplast***
- Liselotte Højgaard, *Professor, Head of clinic, dr.med., **Rigshospitalet, University of Copenhagen & Technical University of Denmark***
- Mads Krogsgaard Thomsen, *Executive VP, **Novo Nordisk***
- Martin Olin, *CFO, **Symphogen***
- Thomas Kongstad Petersen, *VP, **LEO Pharma***



# VISION

## Denmark as a leading life science nation in Europe



### National Growth Strategy for Life Science



Attractive to  
conduct R&D  
in DK



More clinical  
research to  
DK



A top-class  
Danish  
Medicines  
Agency



Better access  
to skilled  
labour



More start-ups  
and digital  
transformation



Targeted  
internationaliza  
tion efforts



A life science office in the Ministry of Industry, Business and Financial Affairs

# A Life Science office in the Ministry of Industry, Business and Financial Affairs



## Primary task:

- Implementation of the life science growth strategy
- Ministerial service
- Analysis and benchmarks
- Initiative about innovative procurement
- Dialogue with stakeholders

## In-house acces to policy areas such as:

- Financing
- Patents and EU-related matters
- Digitalisation
- International labour force
- Business promotion
- Administrative burdens



**UDENRIGSMINISTERIET**  
*Ministry of Foreign Affairs  
of Denmark*

# National Growth Strategy for Life Science



Attractive to  
conduct R&D  
in DK

More clinical  
research to  
DK

A top-class  
Danish  
Medicines  
Agency

Better access  
to skilled  
labour

More start-ups  
and digital  
transformation

Targeted  
internationaliza  
tion efforts

Increased tax  
deductions for  
R&D

New national  
organisation

Increased  
influence in  
HMA & EMA

Technology  
pact includes  
life science

Tax incentives  
in startups &  
SMEs

HealthCare  
Denmark focus  
on life science

Excellent  
research

Reduction of  
trial fees

Increased  
dialogue with  
the LS industry

Better tax  
Scheme: foreign  
researchers

Digital Hub –  
increased use of  
health data

Cooperation  
with health  
authorities



MINISTRY OF INDUSTRY, BUSINESS  
AND FINANCIAL AFFAIRS


# A little more about two of the initiatives





# A new organisation for clinical trials

## Trials initiated by the industry in Denmark (2015)



Source: Copenhagen Economics

# A new organisation for clinical trials

**Trial Nation**  
Clinical Trials Denmark

- **One point of entry** for commercial clinical trials.
- **Fast access (feasibility)**.
- **Patient recruitment** and retention.
- **Advocacy of the benefits** for the hospitals of engaging in commercial clinical trials (improve infrastructure).
- **Stay ahead of new trends** in clinical study designs.
- **Contribute to marketing Denmark** as a clinical trial nation.

# Harnessing the best health data in the world



- **Analyses to shed light on companies' **possibilities** of using health data.**
- **Develop **solutions** to the challenges that companies and researchers experience using health data in the form of, for example, public-private collaboration models**

# Thank you for your attention

Contact: Kasper Lindgaard  
KasLin@em.dk



**MINISTRY OF INDUSTRY, BUSINESS  
AND FINANCIAL AFFAIRS**